STELABEC Supplementary data

Published: 24 November 2021| Version 2 | DOI: 10.17632/6bxhw3hxmf.2
Contributor:
Jonathan London

Description

Supplementary data for the investigator-initiated, prospective, open label , phase 2 STELABEC trial (NCT02648581) evaluating the efficacy and safety of ustekinumab for the treatment of recurrent oral ulcers resistant to colchicine in patients with Behçet disease

Files

Institutions

Assistance Publique - Hopitaux de Paris, Universite de Paris

Categories

Behcet's Syndrome

License